Clinical Trial Success and Delays Risk: Intellia's clinical-stage product candidates may not achieve positive results in ongoing or future clinical trials, or these trials may be subject to significant delays due to unforeseen safety events, enrollment challenges, or trial design issues, which could severely impact their development and potential market entry.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, Intellia's product candidates may not receive necessary regulatory approvals from health authorities like the FDA or EMA, due to stringent safety, efficacy, or manufacturing requirements, leading to significant setbacks and potential abandonment of programs.

Intense Competition Risk: Intellia operates in a highly competitive landscape with other gene-editing companies (e.g., CRISPR Therapeutics, Editas Medicine), traditional pharmaceutical companies, and biotechnology firms developing alternative treatments, which could diminish market share, pricing power, or ability to attract talent and resources.